This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Breast cancer

Chemokine CX3C motif ligand 1 (CX3CL1; fractalkine); HER2 (EGFR2; ErbB2; neu)

Mouse studies suggest inhibiting CX3CL1 could help treat HER2+ breast cancers. In a transgenic mouse model for Her2+ breast cancer, adenovirus-mediated overexpression of Cx3cl1 increased the number of mammary tumors compared with normal expression. In the mouse model, Cx3cl1 knockout delayed tumorigenesis and decreased the number of Her2-driven mammary tumors compared with no knockout. Next steps could include identifying pharmacological inhibitors of CX3CL1.

SciBX 6(27); doi:10.1038/scibx.2013.677
Published online July 18, 2013

Patent and licensing status unavailable

Tardáguila, M. et al. Cancer Res.; published online May 29, 2013;
doi:10.1158/0008-5472.CAN-12-3828
Contact: Santos Mañes, National Center for Biotechnology Information, Madrid, Spain
e-mail:

smanes@cnb.csic.es